Houston-based medical technology firm TYBR Health has successfully closed a $30 million Series A financing round to advance its innovative surgical recovery solutions. The funding was co-led by Vensana Capital and Mutual Capital Partners, with additional support from Neovate Capital Partners and existing investors. These funds are earmarked for expanding commercial access to its FDA-cleared B3 GEL® System and furthering clinical research in orthopedic surgery.
Addressing a Critical Gap in Surgical Recovery
For decades, the primary focus of orthopedic surgery has been on the mechanical repair of damaged anatomical structures. However, the biological healing process that follows an operation significantly influences patient outcomes, including scarring, pain, and functional recovery. Surgeons have traditionally had few tools to manage this critical healing window, representing a significant unmet need in patient care.
TYBR Health aims to fill this void with its B3 GEL® System, a pioneering technology designed to optimize the healing environment. This FDA-cleared product is a flowable extracellular matrix hydrogel that protects tendons, ligaments, and other soft tissues after surgery. Its application is intended to complement precise surgical techniques by managing the biological response during recovery.
Strategic Funding to Fuel Expansion and Research
The $30 million capital infusion provides TYBR Health with substantial resources to execute its strategic growth plans. The round was spearheaded by Vensana Capital and Mutual Capital Partners, demonstrating strong investor confidence in the company's technology and vision. This financing is a pivotal step for the company as it scales its operations and market presence.
The company will allocate the new capital toward several key initiatives aimed at driving adoption and validating its technology. A primary objective is to broaden commercial access, making the B3 GEL® System available to more surgeons across the country. Additionally, the funds will support efforts to expand product indications and finance clinical studies on tissue protection.
Investor Confidence and Market Adoption
Investors have been drawn to TYBR Health's practical solution for a long-standing surgical challenge. Greg Banker, a Partner at Vensana Capital, highlighted the product's ability to adhere where applied and conform to native anatomy. Liz Todia Zambory of Mutual Capital Partners added that the technology addresses a gap surgeons have long lived with.
The B3 GEL® System has already achieved notable commercial traction since its launch, signaling strong market demand. It has been utilized in a variety of orthopedic procedures, including those for the hand, wrist, shoulder, foot, and ankle. This early adoption underscores its value to surgeons seeking straightforward methods to protect healing tissue without complicating procedures.
In connection with the financing, TYBR Health is strengthening its leadership by welcoming two new members to its Board of Directors. Greg Banker of Vensana Capital and Liz Todia Zambory of Mutual Capital Partners will provide strategic guidance to the company. Their appointments are poised to support TYBR Health as it navigates its next phase of commercial and clinical development.
This successful $30 million funding round positions TYBR Health to significantly impact the field of orthopedic surgery. By focusing on the often-overlooked biological phase of recovery, the company is pioneering a new standard of care that complements surgical skill. With expanded resources and a strengthened board, TYBR Health is well-equipped to advance its mission of improving patient healing and long-term outcomes.